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Insulin resistance is characterized by excessive endothelial cell
generation of potentially cytotoxic concentrations of reactive
oxygen species. We examined the role of NADPH oxidase (Nox)
and speciﬁcally Nox2 isoform in superoxide generation in two
complementary in vivo models of human insulin resistance
(endothelial speciﬁc and whole body). Using three complementary
methods to measure superoxide, we demonstrated higher levels of
superoxide in insulin-resistant endothelial cells, which could be
pharmacologically inhibited both acutely and chronically, using the
Nox inhibitor gp91ds-tat. Similarly, insulin resistance–induced im-
pairment of endothelial-mediated vasorelaxation could also be re-
versed using gp91ds-tat. siRNA-mediated knockdown of Nox2,
which was speciﬁcally elevated in insulin-resistant endothelial
cells, signiﬁcantly reduced superoxide levels. Double transgenic
mice with endothelial-speciﬁc insulin resistance and deletion of
Nox2 showed reduced superoxide production and improved vas-
cular function. This study identiﬁes Nox2 as the central molecule
in insulin resistance–mediated oxidative stress and vascular dys-
function. It also establishes pharmacological inhibition of Nox2 as
a novel therapeutic target in insulin resistance–related vascular
disease. Diabetes 62:2130–2134, 2013
Insulin resistance is a multisystem disorder of energyhomeostasis, cell growth, and tissue repair, whichhas been shown to be pivotal to the initiation andprogression of type 2 diabetes (1). As a result, type 2
diabetes is characterized by a portfolio of disorders in-
cluding atherosclerotic coronary artery disease, stroke,
and peripheral vascular disease (2). Atherosclerosis is
characterized by a deleterious change in endothelial cell
phenotype, a hallmark of which is excess generation of
cytotoxic concentrations of reactive oxygen species (ROS)
such as superoxide and failure of endogenous vascular
antioxidant systems to adequately deal with this—a sce-
nario described as oxidative stress (3).
Several studies support a role for insulin resistance in the
generation of pathophysiological concentrations of ROS
and the development of premature atherosclerosis (4). Our
own studies in experimental models of insulin resistance at
a whole-body level and speciﬁc to the endothelium dem-
onstrated that insulin resistance per se is a substrate for
increased generation of ROS and accelerated atheroscle-
rosis (5,6). ROS are thought to promote atherosclerosis
through a number of different mechanisms including but
not limited to enhanced oxidation of lipoproteins, activation
of proinﬂammatory genes, alteration of vascular smooth
muscle cell phenotype, and reduction of bioavailability of
the antiatherosclerotic signaling radical nitric oxide (NO).
A major source of ROS to emerge over the last decade is
NADPH oxidase (Nox) (7,8). Nox was originally identiﬁed
in phagocytes where it exists as a multisubunit complex
consisting of a membrane-bound cytochrome b558 and at
least four cytosolic subunits, which translocate to the
membrane upon activation. It is now clear that the Noxs are
a family of enzymes with each isoform being distinguished
by the membrane-spanning catalytic Nox or Duox subunit
that transfers electrons from NADPH to molecular oxygen,
termed Nox1-Nox5 (8). We have provided evidence that
increased Nox-derived ROS may be a unifying mechanism
underlying insulin resistance–related oxidative stress and
atherosclerosis (5,6). In the current study, we aimed to
examine the therapeutic potential of inhibiting Nox and,
speciﬁcally, Nox2 to reduce oxidative stress and improve
endothelial-dependent vasodilatation in insulin resistance.
RESEARCH DESIGN AND METHODS
Breeding, maintenance of gene-modiﬁed mice, and metabolic testing.
We used male mice with endothelial-speciﬁc mutated (dominant negative) hu-
man insulin receptor (IR) overexpression (ESMIRO) orwith haploinsufﬁciency of
IR at the whole-body level (IR+/2). ESMIRO mice aged 3–5 months (when we
have demonstrated higher ROS generation [6]) and IR+/2 mice aged 6–8 months
(when we have demonstrated signiﬁcantly increased endothelial cell superoxide
generation [5]) were used. All experiments were conducted under U.K. Home
Ofﬁce Project license no. 40/2988. Tail venous blood sampling, glucose, and
insulin tolerance tests were performed as previously described (5,6).
Pulmonary endothelial cell isolation and culture. Pulmonary endothelial cells
(PECs) were isolated by immunoselection with CD146 antibody–coated magnetic
beads using published method and cultured in MV2 medium (Promocell), sup-
plemented with 10% FCS, 100 units/mL penicillin, and 100 mg/mL streptomycin (9).
Pharmacological inhibition of Nox. To inhibit Nox acutely, PEC or aortic
rings were exposed to gp91ds-tat (50 mmol/L for 30 min). For chronic in-
hibition, mice were implanted with osmotic mini-pumps (Alzet), containing
gp91ds-tat or control peptide as previously reported (10). The pump delivered
10 mg/kg/day of drug for 28 days.
Transfection and PCR. PECs were transfected with small interfering RNA
(siRNA) (Nox2: GGUCUUAUUUUGAAGUGUUtt) or scrambled control using
electroporation (Amaxa, Cologne, Germany) and used after 60- to 72-h RNA
isolation, and reverse transcription was performed as we previously described
(9). PCR primer sequences are provided in Supplementary Table 1. SYBR
green–based real-time PCR was performed in an ABI prism 7900HT Sequence
Detection System (Applied Biosystems).
Immunoblotting. Protein extracts were resolved on 4–12% Bis-Tris gels
(Invitrogen) and transferred to polyvinylidene ﬂuoride membranes. Blots were
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probed with primary antibody (Nox2 [BD Biosciences]) or b-actin (Santa
Cruz) and peroxidase-conjugated secondary antibody and developed with
enhanced chemiluminescence (Millipore).
Assessment of superoxide generation
Lucigenin-enhanced chemiluminescence. Superoxide production in PECs
was measured as previously described (5,6). Pellets of PECs were resuspended
in PBS containing 5% FCS and 0.5% BSA, and the luminescence was measured
upon addition of a nonredox cycling concentration (5 mmol/L) of lucigenin and
100 mmol/L NADPH.
Aortic vasomotor function. Vasomotor function was assessed in aortic rings
as previously described (5,6). Rings mounted in an organ bath were equili-
brated at a resting tension of 3 g for 45 min before experiments. Contraction
and relaxation responses were measured by cumulative addition of phenyl-
ephrine (PE) (1 nmol/L to 10 mmol/L) and acetylcholine (Ach) (1 nmol/L to 10
mmol/L); insulin-mediated vasorelaxation in rings preconstricted with PE was
examined as previously reported (6,9).
High-performance liquid chromatographic measurement of conversion of
dihydroethidium to oxyethidium in aorta. With use of previously described
methods, chromatographic separationwas carried out with a NovaPak C18 column
in a high-performance liquid chromatography (HPLC) system (Dionex). Dihy-
droethidium (DHE) was monitored by absorption at 245 nm, and 2-hydroxyethi-
dium and ethidium were monitored by ﬂuorescence detection (11).
Fluorescence-activated cell sorter analysis DHE ﬂuorescence. PECs
were loaded with 10 mmol/L DHE and analyzed by ﬂow cytometry as pre-
viously described (5,6). A minimum of 5,000 events/test was analyzed in
a FACScalibur ﬂow cytometer (Becton-Dickinson).
Statistical methods. Results are expressed as means 6 SEM. All results are
representative of at least three independent repeats. Comparisons were made
using paired or unpaired Student t tests or repeated-measures ANOVA as
appropriate; where repeated t tests were performed, a Bonferroni correction
was applied. P , 0.05 was considered statistically signiﬁcant.
RESULTS
Acute inhibition of Nox reduces superoxide pro-
duction in insulin-resistant endothelial cells. As pre-
viously described (6), aortic relaxation to the endothelium
and NO-dependent vasodilator Ach was blunted in
ESMIRO mice (Fig. 1A). For examination of the effect of
inhibiting Nox on this response, aortic rings were exposed
to gp91ds-tat or scrambled peptide prior to the study.
Gp91ds-tat signiﬁcantly enhanced Ach-induced relaxation
compared with scrambled peptide (Fig. 1A). Also, gp91ds-
tat signiﬁcantly reduced PE-induced contraction (Supple-
mentary Fig. 1A). However, gp91ds-tat did not alter insulin
resistance of ESMIRO aorta as shown by no reduction in
PE-induced contraction response in gp91ds-tat pretreated
rings by insulin treatment (Supplementary Fig. 1B). Su-
peroxide production at baseline measured using lucigenin-
enhanced chemiluminescence in PECs of ESMIRO was
signiﬁcantly greater than in wild-type cells (Fig. 1B). For
examination of the effect of acute inhibition of Nox on
superoxide production, PECs were exposed to gp91ds-tat.
Both gp91ds-tat and nonspeciﬁc antioxidant tiron signiﬁ-
cantly reduced superoxide level in ESMIRO PECs (Fig.
1B). Baseline superoxide measured with DHE using FACS
in PECs (Fig. 1C) and by HPLC in aorta (Fig. 1D) showed
similar results. Blunting of the difference in superoxide
levels when the endothelium of ESMIRO aorta was de-
nuded conﬁrmed that endothelial cells are the primary
source of excessive superoxide in aorta (Supplementary
Fig. 1C).
As previously described (5), IR+/2 mice also had im-
paired Ach-induced aortic relaxation. It was improved af-
ter gp91ds-tat treatment (Fig. 1E). Gp91ds-tat treatment
also improved basal NO bioavailability as shown by a sig-
niﬁcantly higher NG-monomethyl-L-arginine (L-NMMA)–
mediated increase in PE-induced aortic ring contraction
(Supplementary Fig. 2). Both lucigenin assay (in PECs) and
FIG. 1. Acute pharmacological inhibition of Nox in insulin resistance. A: Relaxation curves of aortic rings from ESMIRO mice and wild-type (WT)
littermates with indicated acute treatments in response to Ach (n = 5 each). Normalized superoxide levels in PECs of ESMIRO and WT mice after
acute treatment with gp91ds-tat or scrambled peptide measured by lucigenin-enhanced chemiluminescence assay (B) and FACS-based DHE
analysis (C). D: Normalized oxidized DHE level in aorta of WT and ESMIRO mice after acute treatment with gp91ds-tat or scrambled peptide
measured by HPLC-based DHE analysis. E: Relaxation curves of aortic rings from IR+/2 and wild-type littermates with indicated acute treatments
in response to Ach. Representative trace (F) and mean (G) data showing superoxide levels in PECs of WT and IR+/2 mice measured by lucigenin-
enhanced chemiluminescence after indicated acute treatments. H: Normalized oxidized DHE levels in aorta of WT and IR+/2 mice after acute
treatment with gp91ds-tat or scrambled peptide measured by HPLC-based DHE analysis (*P < 0.05).
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DHE HPLC assay (in aorta) showed higher basal superox-
ide production in IR+/2, which was signiﬁcantly reduced
upon incubation with gp91ds-tat (Fig. 1F–H).
For further examination of the speciﬁc isoform of Nox
responsible for excessive superoxide, PECs from ESMIRO
mice were examined using real-time PCR and Western
blotting. The data showed signiﬁcantly greater expression of
Nox2 mRNA and protein in ESMIRO (Fig. 2A and B) than in
wild-type littermates. Expression of other Nox family genes
was unchanged (Fig. 2A). While analysis of whole aorta and
lung showed similar increments in Nox2 expression, spleen
failed to show any difference (Supplementary Fig. 3A). In
endothelium-denuded ESMIRO aorta, there was no differ-
ence in Nox2 expression (Supplementary Fig. 3B and C),
establishing the localization of excessiveNox2 in aorta as the
endothelium. In PECs of IR+/2 also, Nox2 expression was
higher (Fig. 2C). To conﬁrm that Nox2 is the principal source
of superoxide, we used siRNA to knock down Nox2 in PECs
of ESMIRO. siRNA reduced NOX2 expression but had
no effect on NOX4 expression (Fig. 2D and Supplementary
Fig. 4). Lucigenin-enhanced chemiluminescence conﬁrmed
that Nox2 siRNA signiﬁcantly reduced superoxide genera-
tion in ESMIRO PECs (Fig. 2E and F).
Chronic pharmacological inhibition of Nox enhances
vasomotor function in insulin resistant vessels. To
investigate the therapeutic potential of longer-term inhibition
of Nox, we administered gp91ds-tat or scrambled peptide to
ESMIRO and IR+/2 mice via osmotic mini-pump for 28 days.
Gp91ds-tat had no effect on body mass, organ weight, glu-
cose or insulin tolerance, or plasma insulin (Fig. 3A–C, E,
and G and Supplementary Fig. 5). Gp91ds-tat infusion sig-
niﬁcantly enhanced Ach-induced aortic relaxation compared
with scrambled peptide in ESMIRO and IR+/2 (Fig. 3D and
H). Gp91ds-tat had no effect on SNP-mediated vasore-
laxation (data not shown). For examination of whether
gp91ds-tat induces changes in expression of ROS-related
genes, real-time PCR was performed on RNA isolated from
lungs of ESMIRO mice infused with gp91ds-tat or scrambled
peptide. There was a signiﬁcant decrease in SOD1 expres-
sion in gp91ds-tat treated animals (Supplementary Fig. 6).
Chronic genetic inhibition of Nox2 reduces superoxide
production and enhances vasomotor function. Gp91ds-
tat is thought to be speciﬁc for Nox2 but may affect other
structurally similar Nox isoforms (12). Hence, to examine
the effect of speciﬁcally inactivating Nox2 we generated
ESMIRO/Nox2y/2 by crossing ESMIRO mice with Nox2
holoinsufﬁcient mice (Nox2y/2). Nox2 was successfully
deleted in ESMIRO/Nox2y/2 as shown on both mRNA
(Supplementary Fig. 7A) and protein (Fig. 4A) levels. There
was no difference in behavior, grooming, body weight, or-
gan weight, blood pressure, glucose or insulin tolerance, or
plasma insulin level (Fig. 4B–D and Supplementary Fig. 7B–D).
FIG. 2. Nox expression and acute knockdown of Nox2 in insulin resistance. A: Relative expression of different isoforms of Nox in PECs of wild-type
(WT) and ESMIRO mice (insets, gel electrophoresis of Nox2 and Nox4 gene PCR). B: Normalized data showing Nox2 protein expression in PECs of
WT and ESMIRO mice (n = 4; inset, an example of Nox2 blot and b-actin loading control). C: Relative expression of different isoforms of Nox in
PECs of WT and IR+/2 mice (inset, gel electrophoresis of Nox2 and Nox4 gene PCR). D: Relative expression of Nox2 and Nox4 in PECs of ESMIRO
mice after Nox2 or scrambled siRNA treatment (insets, gel electrophoresis of b-actin, Nox2, and Nox4 gene PCR). Representative trace (E) and
mean (F) data show superoxide levels in PECs of ESMIRO mice after siRNA treatment (*P < 0.05).
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Lucigenin-enhanced chemiluminescence showed that basal
superoxide level was signiﬁcantly reduced in ESMIRO/
Nox2y/2 PECs compared with ESMIRO (Fig. 4E). HPLC
assay also showed a similar result in aorta of ESMIRO/
Nox2y/2 mice. Aortic rings from ESMIRO/Nox2y/2 mice had
signiﬁcantly enhanced Ach-induced relaxation compared
with ESMIRO (Fig. 4G). Real-time PCR analysis of RNA
isolated from ESMIRO/Nox2y/2 and ESMIRO lungs showed
a signiﬁcant decrease in SOD1 expression in ESMIRO/
Nox2y/2 (Supplementary Fig. 8).
DISCUSSION
The principal ﬁndings of the present report are as follows:
1) Acute and chronic inhibition of Nox using an inhibitory
peptide reduces oxidative stress and restores defective
vasomotor function in complementary in vivo models of
insulin resistance. 2) Acute knockdown of Nox2 reduces
oxidative stress in insulin-resistant endothelial cells. 3)
Deletion of Nox2 in vivo restores aortic vasomotor func-
tion and reduces oxidative stress. 4) Chronic inhibition of
Nox or Nox2 has no effect on glucose homeostasis.
Both Nox2 and Nox4 are expressed in the endothelium
and may contribute to ROS production. We previously
demonstrated increased Nox4 mRNA expression in coro-
nary microvascular endothelial cells from ESMIRO mice
(6). Nox4 has been shown to be regulated at an mRNA
level and have a unique pattern of ROS generation (13) and
could therefore contribute to insulin resistance–related
oxidative stress. Here, we show that speciﬁcally inhibiting
Nox2 as opposed to Nox4 restored vascular function in
insulin-resistant mice. This is of particular importance, as
Nox4 may have favorable effects on vascular function (11)
and angiogenesis (14).
This report and our previously published work now
provide a unifying mechanism for the oxidative stress as-
sociated with insulin resistance. In obese mice (15) and
lean mice with whole-body (5) and endothelium-speciﬁc
(6) insulin resistance, we have demonstrated reduced NO
bioavailability and increased superoxide generation. The
principal source of superoxide was Nox. Consistent with
these studies, Nox has recently emerged as a major source
of superoxide in insulin-resistant humans (16,17). Despite
compelling experimental evidence supporting a role for
ROS in atherosclerosis, clinical trials of antioxidants have
been disappointing (18). In this context, our study showing
favorable effects of speciﬁcally targeting Nox2 isoform of
NADPH oxidase in insulin resistance–associated endothe-
lial cell dysfunction gains signiﬁcant importance.
In conclusion, we have demonstrated that inhibiting Nox
and speciﬁcally Nox2 in vivo improves endothelial cell
function in mice with insulin resistance. This approach did
not adversely affect glucose homeostasis. Our data estab-
lish Nox2 as an attractive target to prevent early athero-
sclerosis in insulin resistance.
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FIG. 3. Chronic pharmacological inhibition of Nox in insulin resistance. A: Body weights. B: Glucose tolerance test. C: Insulin tolerance test of
ESMIRO mice infused with gp91ds-tat or scrambled peptide via osmotic mini-pump. D: Relaxation curves of aortic rings from ESMIRO mice infused
with gp91ds-tat or scrambled peptide in response to Ach. E: Body weight. F: Glucose tolerance test. G: Insulin tolerance test of IR+/2 mice infused
with gp91ds-tat or scrambled peptide via osmotic mini-pump. H: Relaxation curves of aortic rings from IR+/2 mice infused with gp91ds-tat or
scrambled peptide in response to Ach (*P < 0.05).
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